Your browser doesn't support javascript.
loading
Vortex Keratopathy in a Patient Receiving Vandetanib for Non-Small Cell Lung Cancer
Article in En | WPRIM | ID: wpr-15768
Responsible library: WPRO
ABSTRACT
We report a case of vortex keratopathy in a patient treated with vandetanib for non-small cell lung cancer (NSCLC). A 44-year-old female who underwent two cycles of chemotherapy for NSCLC complained of visual blurring in both eyes after the initiation of vandetanib, an anti-epidermal growth factor receptor (EGFR) and anti-vascular endothelial growth factor receptor 2 protein tyrosine kinase inhibitor. On ophthalmic examination, visual acuities were 20 / 20 OU and, with the exception of diffuse vortex keratopathy in both eyes, other findings were unremarkable. Vandetanib is believed to have caused vortex keratopathy in this patient. Anti-EGFR properties affecting normal corneal epithelial cell migration and wound healing or drug associated metabolite deposition, which is the case in numerous drug-associated vortex keratopathies, may be possible underlying mechanisms in the formation of this corneal complication.
Subject(s)
Key words
Full text: 1 Index: WPRIM Main subject: Piperidines / Quinazolines / Visual Acuity / Follow-Up Studies / Carcinoma, Non-Small-Cell Lung / Cornea / Corneal Diseases / Microscopy, Acoustic / Diagnosis, Differential / Dose-Response Relationship, Drug Type of study: Diagnostic_studies / Observational_studies / Prognostic_studies Limits: Adult / Female / Humans Language: En Journal: Korean Journal of Ophthalmology Year: 2011 Type: Article
Full text: 1 Index: WPRIM Main subject: Piperidines / Quinazolines / Visual Acuity / Follow-Up Studies / Carcinoma, Non-Small-Cell Lung / Cornea / Corneal Diseases / Microscopy, Acoustic / Diagnosis, Differential / Dose-Response Relationship, Drug Type of study: Diagnostic_studies / Observational_studies / Prognostic_studies Limits: Adult / Female / Humans Language: En Journal: Korean Journal of Ophthalmology Year: 2011 Type: Article